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Zn-2-glycoprotein (ZAG) is a member of the major
histocompatibility complex (MHC) class I family of pro-
teins and is identical in amino acid sequence to a tumor-
derived lipid-mobilizing factor associated with cachexia
in cancer patients. ZAG is present in plasma and other
body fluids, and its natural function, like leptin’s, prob-
ably lies in lipid store homeostasis. X-ray crystallogra-
phy has revealed an open groove between the helices of
ZAG’s 1 and 2 domains, containing an unidentified
small ligand in a position similar to that of peptides in
MHC proteins (Sanchez, L. M., Chirino, A. J., and Bjork-
man, P. J. (1999) Science 283, 1914–1919). Here we show,
using serum-derived and bacterial recombinant protein,
that ZAG binds the fluorophore-tagged fatty acid 11-
(dansylamino)undecanoic acid (DAUDA) and, by compe-
tition, natural fatty acids such as arachidonic, linolenic,
eicosapentaenoic, and docosahexaenoic acids. Other
MHC class I-related proteins (FcRn, HFE, HLA-Cw*0702)
showed no such evidence of binding. Fluorescence and
isothermal calorimetry analysis showed that ZAG binds
DAUDA with Kd in the micromolar range, and differen-
tial scanning calorimetry showed that ligand binding
increases the thermal stability of the protein. Addition
of fatty acids to ZAG alters its intrinsic (tryptophan)
fluorescence emission spectrum, providing a strong in-
dication that ligand binds in the expected position close
to a cluster of exposed tryptophan side chains in the
groove. This study therefore shows that ZAG binds small
hydrophobic ligands, that the natural ligand may be a
polyunsaturated fatty acid, and provides a fluorescence-
based method for investigating ZAG-ligand interactions.
Zn-2-glycoprotein (ZAG)
1 is a soluble protein present in
serum and other body fluids (1, 2). It accumulates in breast
cysts, is produced by 40% of breast carcinomas, and is inducible
in breast cancer cell lines by glucocorticoids and androgens (2,
3). ZAG is identical in amino acid sequence to lipid-mobilizing
factor that is associated with cachexia (4, 5), the wasting syn-
drome involving depletion of adipose and muscle tissue, such as
occurs in many patients with cancer, AIDS, trypanosomiasis,
and other life-threatening diseases. Significantly, ZAG is over-
expressed in tumors that accompany fat loss, and exogenous
ZAG produces cachectic symptoms in experimental animals (4,
5). ZAG, like leptin (6), therefore, participates in lipid store
homeostasis, the dysregulation of which has serious implica-
tions for survival and the management of cancer and other
diseases.
ZAG is a member of a family of proteins typified by the class
I MHC proteins (which present peptides to cytotoxic T cells) (7)
and includes CD1 (which presents lipidic antigens to T cells) (8,
9), the neonatal Fc receptor (FcRn; involved in transportation
of immunoglobulin across epithelia), and HFE (a transferrin-
binding protein that regulates iron homeostasis) (10, 11). In
contrast to all other MHC-like proteins, ZAG and MIC-A (a
divergent member of the MHC family) are not found in associ-
ation with 2-microglobulin (2M) as a light chain (12, 13).
The crystal structure of ZAG reveals an overall fold that is
very similar to that of MHC class I molecules (14). The spatial
relationship between its three domains is slightly different
from that found in class I MHC proteins, which may explain
the lack of affinity of ZAG for 2M. As with all members of the
family, a prominent feature of the 1 and 2 domains is a pair
of opposing -helices that enclose the binding groove for pep-
tides or (glyco)lipids in MHC proteins. In FcRn, HFE, and
MIC-A, the groove is closed, and there is no evidence for ligand
binding within the region between the helices, although each
interacts with other proteins (15–17). In ZAG, however, the
x-ray crystal structure shows that the groove is open and con-
tains an additional electron density ascribed to an unidentified
ligand (Fig. 1) (14). The presumptive ligand appears curved and
nonbranched and lacks the characteristic protrusions of either a
peptide or carbohydrate structure. The molecular surface of the
central part of the groove where the unresolved density lies is
nearly neutral in charge, except for an Arg side chain protrud-
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ing from one side of the groove. The other residues surrounding
the presumptive ligand are hydrophobic (three Trp, four Tyr,
two Phe, and an Ile). Like CD1, therefore, ZAG may bind a
hydrophobic ligand, although the groove in ZAG is not as deep
as that in CD1 and could not accommodate lipids of the size and
complexity of those bound by this protein.
The nature of the ZAG ligand cannot be determined unam-
biguously from the crystal structure, because the electron
density corresponding to the ligand may arise from a hetero-
geneous mixture of molecules or represent a loosely bound or
large ligand only partially inserted into the groove. The nature
of the ligand or ligands is clearly of potential importance to the
biological function of ZAG. Moreover, if (like MHC class I) ZAG
can bind different ligands of a biochemically similar class, then
it is possible that the biological activity of ZAG varies with the
precise nature of the bound compound. The nature of the ligand
would be of relevance to homeostasis of body lipid stores and
the management of disease conditions in which ZAG activity is
detrimental to outcome.
Given the chemical characteristics of the groove, and assum-
ing that the unresolved electron density is a useful guide to the
nature of the ligand, it is conceivable that the ligand is a fatty
acid. Using fluorescent methods and microcalorimetry, we have
found that ZAG can bind fatty acids and that one particular
fluorescent fatty acid analogue may be particularly useful for
screening ZAG ligands.
EXPERIMENTAL PROCEDURES
Naturally Produced and Recombinant Proteins—Natural ZAG was
purified from human serum using immunoaffinity chromatography as
described previously (13). For expression of ZAG in Escherichia coli,
polymerase chain reaction (PCR) was used to modify the cDNA encod-
ing human ZAG to insert a 5 NdeI site before the codon corresponding
to residue 1 of the mature protein and a 3 XhoI site following the stop
codon. The PCR product was subcloned into pPCR-Script Amp SK()
and sequenced, then subcloned into the NdeI and XhoI sites of the
bacterial expression vector pET23a (Novagen). ZAG was expressed in
E. coli strain BL21(DE)3pLysE, and the protein was renatured from
inclusion bodies as described previously (18) and purified on a gel
filtration column (HiLoadTM 26/60 Superdex 200 column; Amersham
Pharmacia Biotech). The protein migrated as a single peak on the gel
filtration column and exhibited a far-UV circular dichroism spectrum
similar to natural ZAG isolated from serum (data not shown). Soluble
versions of FcRn, HFE, and a class I MHC protein (HLA-Cw*0702) were
expressed in CHO cells (FcRn and HFE) or baculovirus-infected insect
cells (HLA-Cw*0702) and purified as described previously (16, 19, 20).
All the proteins were greater than 95% pure as judged by SDS-poly-
acrylamide gel electrophoresis stained with Coomassie Blue. The con-
centrations of the proteins were estimated by absorbance at 280 nm
using theoretical extinction coefficients based on their amino acid com-
positions (21) using the ProtParam program through ExPASy server
(expasy.cbr.nrc.ca/tools/).
Ligands—The fluorescent fatty acids 11-((5-dimethylaminonaphtha-
lene-1-sulfonyl)amino)undecanoic acid (DAUDA) and cis-parinaric acid
were obtained from Molecular Probes (Eugene, OR). Oleic acid, arachi-
donic acid, docosahexaenoic acid, -linolenic acid, cis-eicosapentaenoic
acid, linoleic acid, palmitic acid, all-trans-retinol, and dansyl--amino-
octanoic acid (DACA) were obtained from Sigma (Poole, Dorset, UK).
The dansylated fatty acids were stored as stock solutions of3 mg ml1
in ethanol, in the dark at 20 °C, and freshly diluted in phosphate-
buffered saline (PBS; 171 mM NaCl, 3.35 mM KCl, 10 mM Na2HPO4, 1.8
mM KH2PO4, pH 7.2) to 1 M before use in the fluorescence experi-
ments. Competitors of fluorescent fatty acid binding were prepared as
stock solutions in ethanol at 10 mM and diluted in PBS in the case of
oleic acid or in ethanol for other competitors. Retinol was dissolved and
diluted in ethanol immediately before use and binding to proteins was
tested by addition of, typically, 5 l of this directly to a cuvette contain-
ing protein in PBS. The concentrations of both DAUDA and DACA
stocks were calculated using a molar extinction coefficient 335 of 4800
M1 cm1 in methanol, 303 of 76,000 M
1 cm1 for cis-parinaric acid in
ethanol (22), and 325 of 52,480 M
1 cm1 for retinol in ethanol.
Spectrofluorimetry and Fluorescence-based Ligand Binding—Fluo-
rescence binding emission spectra (uncorrected) were recorded at 20 °C
with a SPEX Fluo-Max spectrofluorimeter (Spex Industries, Edison,
NJ) using 2-ml samples in a silica cuvette. Raman scattering by solvent
water was subtracted where necessary. The excitation wavelengths
used for DAUDA, DACA, cis-parinaric acid, and retinol were 345, 345,
319, and 350 nm, respectively. Fluorescence data were corrected for
dilution where necessary and fitted by standard nonlinear regression
techniques (using Microcal ORIGIN software) to a single site binding
model to give estimates of the dissociation constant (Kd) and maximal
fluorescence intensities (Fmax).
Isothermal Calorimetry (ITC)—ITC experiments to measure the
binding of DAUDA to ZAG were done at 25 °C using a Microcal VP-ITC
titration microcalorimeter following standard instrumental procedures
(23, 24) with a 250-l injection syringe and 320 rpm stirring. Proteins
were dialyzed against PBS, followed by addition of ethanol to match the
ligand mixture (2.5%), and degassed briefly before loading into the
calorimeter cell. Ligand (DAUDA) solutions were made up from etha-
nolic stock solutions by dilution (to 2.5% ethanol) in the same buffer. A
typical binding experiment involved 25  10-l injections of ligand
solution (450 M) into the ITC cell (1.4 ml active volume) containing
protein (25 M). Control experiments were performed under identical
conditions by injection of ligand into buffer alone (to correct for heats of
ligand dilution) and injection of buffer into the protein mix (to correct
for heats of dilution of the protein). Integrated heat effects, after cor-
rection for heats of dilution, were analyzed by nonlinear regression in
terms of a simple single-site binding model using the standard Microcal
ORIGIN software package. For each thermal titration curve this yields
estimates of the apparent number of binding sites (n) on the protein, the
binding constant (K/M1) and the enthalpy of binding (H/kcal mol1).
Other thermodynamic quantities were calculated using standard ex-
pressions: G0  RTlnK  H0  TS°.
Differential Scanning Calorimetry (DSC)—DSC to examine the ther-
mal stability of ZAG and ZAGDAUDA complexes was done using a
Microcal VP-DSC, normally scanning from 10 to 100 °C with a scan rate
of 60 °C h1 (25). Scans were repeated after cooling with the sample in
situ to check for reversibility of the thermal unfolding transition. Pro-
tein samples (12.5 M) were prepared as above for ITC, and both sample
and reference (buffer) solutions were degassed prior to loading. In
experiments with added ligand, the samples also contained ethanol
(0.5–5%, depending on ligand addition), and separate control experi-
ments were performed to confirm the absence of any significant ethanol
effect on protein stability under these conditions. Normalized DSC
data, corrected for instrumental baseline, were fitted to standard non-
two-state models using Microcal ORIGIN software.
FIG. 1. The presumptive ligand binding site on ZAG. A view of
the 1 and 2 domains of ZAG showing the position of the unresolved
density found in the crystal structure (brown net) (14) is shown. The
amino acid side chains that may interact with the ligand are repre-
sented as balls-and-sticks. Note the position of the cluster of trypto-
phans (W115, W134, W148) close to one end of the density, and the
prominent arginine side chain (R73) at the opposite end.
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RESULTS AND DISCUSSION
Human serum-derived and recombinant ZAG, and control
proteins of the MHC family, were obtained as detailed under
“Experimental Procedures.” The naturally produced and
recombinant ZAG behaved similarly in preliminary ligand
binding and intrinsic fluorescence experiments, and only ex-
periments using the natural protein are described unless dif-
ferences were noted.
Fatty Acid Binding—Synthetic fatty acid analogues bearing
environment-sensitive fluorophores were used to investigate
fatty acid binding by ZAG. These compounds alter their fluo-
rescence emission intensities and wavelengths of peak emis-
sion upon entry into protein binding sites. The most useful
proved to be DAUDA, which is a saturated fatty acid with a
dansyl fluorophore attached at its -methyl terminus, and has
been used extensively in the study of fatty acid-binding pro-
teins, from which it can be displaced by specific fatty acids (26,
27). DAUDA also binds to serum albumins, although it appears
in this case to bind in the hydrophobic binding site for bilirubin
(28). Addition of ZAG to a solution of DAUDA was accompanied
by a substantial increase in DAUDA fluorescence intensity and
a shift in the fluorescence emission maximum wavelength from
543 to 512 nm (Fig. 2A). Control experiments with FcRn, HFE,
or HLA-Cw*0702 under similar conditions gave no alteration
in the fluorescence emission by DAUDA.
The blue shift in fluorescence emission of the dansyl fluoro-
phore indicates transfer from solvent water to an apolar pro-
tein binding site. A blue shift to 512 nm with DAUDA is
substantial, but is less than that observed upon DAUDA bind-
ing to liver or intestinal fatty acid binding proteins (496 and
492 nm, respectively) (29, 30), tear lipocalin (490 nm) (31); the
most extreme blue shifts in DAUDA emission have been re-
corded upon interaction with unusual lipid-binding proteins
from nematode worms (475 and 485 nm) (32–34). The relatively
small blue shift when DAUDA interacts with ZAG is perhaps
indicative of a binding site that is more solvent-exposed than in
lipid transporter proteins, such as would be expected for an
open-sided binding groove. ZAG failed to produce any detect-
able change in the fluorescence emission of a fatty acid ana-
logue in which the dansyl group is attached at the -carbon
(dansyl-D,L--amino-octanoic acid) or in the fluorophore alone
(in the form of dansylamide). Consequently, dansylation close
to the carboxylate of a fatty acid interferes with binding, and
the dansyl group itself probably does not contribute to the
binding. Fluorescence titration experiments in which ZAG
was added incrementally to a solution of DAUDA provided an
estimate of the DAUDAZAG dissociation constant (Kd 
4.2  107 M; data not shown), which was similar to that
obtained from calorimetry (see below).
Addition of natural fatty acids to a ZAGDAUDA complex
resulted in a reversal of the fluorescence effect, presumably by
competitive displacement of DAUDA into solvent (Fig. 2B).
Different fatty acids varied in the efficiency with which they
did this on a molar basis, the ranking being docosahexaenoic 
eicosapentaenoic  linolenic 	 arachidonic  linoleic  oleic
acid, but no changes were detected upon addition of cholesterol,
deoxycholic acid, or arterenol (noradrenaline). ZAG was found
to increase the fluorescence of ANS, which is generally re-
garded as a probe for exposed hydrophobic surfaces on proteins,
and this change was also reversed upon addition of fatty acids
(data not shown). ZAG failed to alter the emission of the in-
trinsically fluorescent steroid dehydroergosterol (which binds
to liver fatty acid-binding protein (35)), all-trans-retinol, 12-
(9-anthroxyl)stearic acid (which binds to several different fatty
acid-binding proteins (36, 37)), or cis-parinaric acid. The latter
result is surprising given that cis-parinaric acid is known to
bind to other fatty acid-binding proteins, including those that
do not bind DAUDA (38). This may, however, be due to the fact
that this fatty acid is highly conjugated and may lack the
conformational freedom to adapt to the ZAG binding site. Ei-
cosanoids such as arachidonic acid, in contrast, are known to be
more flexible and bind to proteins in different conformations.
For instance, arachidonic acid binds in a hairpin conformation
in adipocyte lipid-binding protein (39), but in a more extended
conformation in prostaglandin synthase, as does leukotriene A4
in leukotriene A4 hydrolase (40, 41).
Soluble forms of proteins belonging to the MHC class I fam-
ily, such as FcRn, HFE, and an MHC molecule (HLA-Cw*0702)
all failed to bind DAUDA and ANS in control experiments.
Thus, ZAG appears to specifically bind hydrophobic ligands,
with an apparent preference for fatty acids, although many
more types of natural ligand need to be tested for its true
specificity to be understood. DAUDA may or may not bind to
ZAG in a fashion analagous to its natural ligand(s), but it is
likely to be useful in screening for natural ligands by compet-
itive displacement. The characteristics of its interaction with
ZAG were therefore investigated further.
Binding Affinity and Stoichiometry—ITC experiments
showed that binding of DAUDA to ZAG is exothermic at 25 °C,
giving thermal titration curves consistent with simple 1:1 com-
plex formation (Fig. 3). Mean thermodynamic parameters for
FIG. 2. Fluorescence analysis of ligand binding by ZAG. A,
fluorescence emission spectra (Exc  345 nm) of 2 M DAUDA alone in
buffer or upon addition of 0.39 M ZAG. The difference spectrum indi-
cates the wavelength of peak emission by DAUDA when bound to ZAG.
Other proteins structurally related to ZAG (FcRn, HFE, and the class I
MHC molecule HLA-Cw*0702) produced no change in the fluorescence
emission spectrum of DAUDA, and the effect of FcRn is given for
example. B, the reversal of ZAG-induced changes in DAUDA emission
by competition with 20 M arachidonic, linoleic, linolenic, eicosapentae-
noic (EPA), or docosahexaenoic (DHA) acids added to a preformed
complex of ZAGDAUDA complex. The concentrations of DAUDA and
ZAG were 2 and 0.39 M, respectively.
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binding of DAUDA to ZAG, determined from a series of calori-
metric experiments, are: Kd  1.3 (
0.4) M, H
0  5.2
(
1.0) kcal mol1, S°  9.7 (
3.8) cal K1 mol1 (1 cal 
4.184 J). These data are consistent with the micromolar disso-
ciation constants determined from the DAUDA fluorescence
titrations and confirm that fluorescence methods, although
intrinsically indirect and less precise than direct calorimetric
methods, are sufficiently robust to be used for routine ligand
binding studies in this system. The positive S0 for binding is
consistent with an increase in solvent (water) entropy antici-
pated due to disruption of the hydration layer around the
hydrophobic ligand.
ITC experiments using the natural ligands were not feasible
under the conditions used because of the poor solubility of the
ligands at the concentrations required in the injection syringe.
The serum-derived ZAG used here for binding studies was
purified using similar procedures to those used for the original
crystallographic work (though lacking the additives used for
protein crystallization) and may be similarly loaded with com-
peting natural (endogenous) ligand. Bacterial recombinant
ZAG may also be loaded with the same or a related compound
derived from the synthesizing cells. Although we have no direct
evidence for such endogenous ligand(s) in our preparations,
any competition for the binding site would serve only to reduce
the apparent binding affinities for exogenous ligands that we
have observed. The good fit of fluorescence and ITC titration
data to simple binding models, with n  1 stoichiometry,
shows that endogenous ligand (if present) is exchangeable with
DAUDA or natural fatty acids and would act simply as a
competitive inhibitor in binding affinity studies. Consequently,
the apparent ligand dissociation constants (Kd) determined
here represent an upper limit for the true Kd, and the binding
strength of ZAG for the natural ligand may be substantially
stronger. Given that the Kd values obtained for ZAGDAUDA
were of a similar order of magnitude (micromolar) to those
measured for interactions between lipids and lipid transport
proteins (26, 27), the binding may be sufficiently strong for the
ZAGligand complex to remain intact during its passage from
the synthesizing cell through blood and tissue spaces to the
target cells.
ZAG Stability and Ligand Binding—DSC experiments (Fig.
4) showed that ZAG proteins undergo a typical endothermic
cooperative reversible unfolding transition in solution with a
transition midpoint (Tm) at around 65–70 °C under physiolog-
ical conditions. Recombinant ZAG samples had the slightly
lower thermal stability (Tm 65 °C) compared with serum-de-
rived material (Tm 70 °C) under the same conditions, possibly
because the recombinant proteins lack the ligand or N-linked
carbohydrates (14). The crystal structure of ZAG shows nine
ordered carbohydrate residues arranged in a biantennary ar-
rangement, attached to Asn239 on a loop in the 3 domain
directly beneath the platform formed by the 1-2 superdo-
main, and other sites with N-linked carbohydrates are also
evident (14). The reduced stability of the bacterial recombinant
ZAG is therefore probably due to the absence of these glycosy-
lations, although the DSC data and the intrinsic fluorescence
spectra (see below) indicate that the recombinant protein back-
bone is properly folded. Addition of increasing concentrations of
DAUDA raised the protein Tm progressively for both the nat-
ural and recombinant ZAG by up to 5 °C with 200 M added
ligand. This is typical of the enhancement in protein folding
stability generally observed in the presence of ligands that bind
specifically to the native state (25). It is important to empha-
size here that the enhanced stability of the protein-ligand com-
plex does not necessarily imply any conformational change in
the protein (as is sometimes assumed), rather it represents
simply the additional free energy required to dissociate the
native protein-ligand complex before the protein can unfold.
Intrinsic Fluorescence and the Position of the Fatty Acid
Binding Site—The results detailed above strongly indicate that
DAUDA binds to ZAG at a hydrophobic binding site, from
which it is displaceable by fatty acids. The simplest hypothesis
is that the binding site is in the groove lying between the 1 and
2 domains, analogous to the peptide or lipid ligand binding
sites of class I MHC molecules. The binding data, however,
provide no direct evidence that this is the binding site in ZAG,
and it is conceivable that DAUDA and fatty acids bind else-
where on the protein. We therefore exploited intrinsic trypto-
phan fluorescence in an attempt to localize the binding site.
ZAG possesses eight tryptophans, three in the 3 domain, two
at the extreme end of the groove and distant from the region
FIG. 3. ITC analysis of ZAG-ligand interaction. Typical ITC ther-
mograms for sequential 10-l additions of DAUDA (450 M) to ZAG
(25 M). The upper panel shows raw data, with negative heat pulses
indicating exothermic binding, decreasing to base-line levels at higher
ligand concentrations. The lower panel shows integrated heats, giving a
differential binding curve. The line shows the best fit to these data
using a single-site binding model with n  0.99, K  6.7  105 M (Kd 
1.5 M), H  3.99 kcal mol1, S0  13.3 cal K1 mol1.
FIG. 4. Increased thermal stability of ZAG upon ligand bind-
ing. Normalized DSC data, corrected for buffer base line showing
cooperative endothermic unfolding of wild-type (A) and recombinant
ZAG (B) in the presence and absence of 0.2 mM DAUDA.
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occupied by the unresolved density, and three more that are
closely grouped together in the groove immediately adjacent to
the density. The intrinsic fluorescence emission spectrum of
ZAG (Exc  290 nm) peaked at 340 nm, and there was a
gradual quenching and blue shift in max with successive ad-
ditions of arachidonic acid (Fig. 5); a similar spectral shift was
found upon addition of docosahexaenoic acid (not shown). Sub-
traction of the spectrum of ZAG in the absence of added fatty
acid from that of a ZAG/arachidonic acid mixture provided a
spectrum peaking at 353 nm. This is indicative of the quench-
ing of tryptophans upon ligand binding and that the trypto-
phans concerned emit at 353 nm in the absence of ligand.
Emission at this wavelength is indicative of a tryptophan side
chain fully exposed to solvent water (42, 43), such as would be
observed in tryptophan in solution or the tryptophans in a fully
unfolded protein. Such an effect would occur if the ligand were
to alter the charge environment of a tryptophan side chain or if
binding were to induce a conformational change in the protein.
In either case, the results strongly indicate ligand binding at a
site close to, or congruent with, the position of the unresolved
density.
These data demonstrate that ZAG can bind hydrophobic
compounds and that the natural ligand may be a fatty acid,
possibly a polyunsaturated fatty acid (PUFA). These findings
are mainly based on the binding by ZAG of a synthetic fluores-
cent fatty acid, DAUDA. The characteristics of this interaction,
as quantified here by fluorescence and microcalorimetry, pro-
vide a basis for the screening of natural compounds for binding
to ZAG by competitive displacement of DAUDA from the ZAG
binding site. Use of this approach showed that ZAG can bind
several different types of fatty acids, all of which are abundant
in human tissues. Any preparation of ZAG will probably there-
fore contain a heterogeneous mixture of fatty acids, which
would thereby provide an explanation for the failure to resolve
the density found in crystals of ZAG. Even if DAUDA were not
of the same generic class as ZAG’s true ligand(s), and fatty
acids are not relevant in vivo, DAUDA may nevertheless be
valuable for the screening of hydrophobic compounds, natural
or synthetic, for binding to ZAG.
The shape and chemical environment of the unresolved
electron density in the crystal structure of ZAG show charac-
teristics commensurate with a fatty acid; it is a curved, non-
branched tube, which is embedded in a groove near a cluster of
hydrophobic amino acids. Moreover, the only prominent
charged amino acid side chain projecting into the groove is an
arginine (Arg73), which is positioned 4.5 Å from one end of the
density. Args and Tyrs are commonly involved in anchoring
fatty acids in binding proteins. For example, the carboxylate of
arachidonic acid is anchored by interactions with a pair of Arg
side chains and a Tyr in adipocyte lipid-binding protein (39)
and in prostaglandin synthase by a salt bridge to an Arg and a
hydrogen bond to the OH group of a nearby Tyr (40), arrange-
ments that are also possible in ZAG.
If, like class I MHC molecules and CD1, ZAG binds a variety
of ligands in vivo, albeit of a single generic class (peptides for
class I, large, complex lipids for CD1), then it is possible that
the particular fatty acid bound to ZAG may determine its
biological effect. PUFAs in particular are notable for their
pharmacological effects, and it is perhaps worthy of note that
the fatty acid found to bind best to ZAG was DHA, which has
recently been found to be an activation ligand for the retinoid X
receptor in mouse brain (44). It may also be pertinent that
eicosapentaenoic acid (which also binds well to ZAG) in con-
junction with tumor-derived lipid mobilizing factor induces
lipolysis in cultured adipocytes, whereas DHA has no such
activity (45, 46). It may therefore be possible to manipulate the
biological effects of endogenous ZAG in clinical situations (such
as cachexia) by direct administration of an appropriate ZAG-
binding ligand or of an appropriate ZAGligand complex.
All of the class I-type proteins require binding to a specific
receptor for their biological activity to be fulfilled. No receptor
has yet been described for ZAG, but it is conceivable that
interaction with a receptor can be modified (favored or inhib-
ited) by the presence of ligand and that the particular ligand so
delivered then specifies the biologically activity of the recipient
cell. An intriguing possibility, however, is that there is more
than one receptor for ZAG and that different receptors discrim-
inate different ZAGligand combinations, in an analagous
fashion to MHC class Ipeptide and CD1lipid combinations
interacting with their specific T cell receptor. The particular
receptor activated may then determine the biological effect.
Whatever the case, it is clearly important to establish the range
of ligands that can bind to ZAG, those important in vivo, and
how the biological effects of ZAG can be manipulated.
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